GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares opened today ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024. GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...